Processing...
Clinical Trials for Ovarian Cancer
Search
Search
There are 216 active trials for advanced/metastatic ovarian cancer.
Click on a trial to see more information.
216 trials meet filter criteria.
Sort by:
HealthScout AI summary: Adults with metastatic or unresectable solid tumors harboring AKT/PI3K/PTEN pathway alterations (excluding concurrent EGFR/KRAS/NRAS/HRAS/BRAF drivers) receive the investigational AKT-pathway inhibitor TER-2013 as monotherapy (expansion in ovarian/cervical/SCCHN/lung/esophageal and endometrial cancers) or with fulvestrant for HR+/HER2- breast cancer previously treated with an aromatase inhibitor. Prior AKT/PI3K/PTEN inhibitors (and prior SERD/mTOR in combo expansion) are excluded; requires ECOG 0–1 and adequate organ function.
ClinicalTrials.gov ID: NCT07109726
HealthScout AI summary: Adults with advanced solid tumors harboring AKT1 E17K mutations, including a cohort with HR+/HER2- metastatic breast cancer, receive the oral selective AKT1 E17K allosteric inhibitor ATV-1601 as monotherapy or in combination with fulvestrant. The trial excludes tumors with activating RAS/BRAF mutations and aims to identify dosing and preliminary activity while minimizing AKT2-related metabolic toxicities.
ClinicalTrials.gov ID: NCT07038369
HealthScout AI summary: Adults with mesothelin-expressing advanced solid tumors (ECOG 0–1) receive weekly IV CT-95 (LNK-101), a mesothelin × CD3 T‑cell–engaging bispecific antibody engineered for reduced off‑tumor activation, in a dose-escalation/expansion study. Excludes prior mesothelin-targeted CD3/CAR‑T therapy; evaluates safety, PK, and preliminary efficacy across tumor types including mesothelioma.
ClinicalTrials.gov ID: NCT06756035
HealthScout AI summary: Adults with mesothelin-expressing recurrent/relapsed advanced ovarian (including primary peritoneal/fallopian tube), cholangiocarcinoma, or epithelial mesothelioma (pleural/peritoneal), ECOG 0–1, after ≥1 prior therapy, receive lymphodepleting chemotherapy followed by a single infusion of SynKIR-110, an autologous T-cell therapy using a mesothelin-targeted KIR-CAR (activating KIR plus DAP12) designed to enhance persistence/function in solid tumors. Excludes prior gene-engineered T-cell therapy, sarcomatoid/biphasic mesothelioma, active viral infections, significant pulmonary disease, and active autoimmune disease.
ClinicalTrials.gov ID: NCT05568680
HealthScout AI summary: Adults with TROP2-positive, platinum-resistant ovarian/peritoneal/fallopian tube cancer, mesonephric-like adenocarcinoma, or pancreatic/ampullary cancer with peritoneal/retroperitoneal disease receive lymphodepleting cyclophosphamide/fludarabine followed by a single intraperitoneal infusion of allogeneic cord blood–derived NK cells engineered with a TROP2-directed CAR and IL-15 for persistence. Designed to assess safety and preliminary efficacy of intraperitoneal TROP2 CAR-NK in heavily pretreated patients without active CNS disease or contraindications to IP therapy.
ClinicalTrials.gov ID: NCT05922930
HealthScout AI summary: Adults with advanced, HLA‑G–positive solid tumors (ECOG 0–1) after standard therapies receive leukapheresis, fludarabine/cyclophosphamide lymphodepletion, then a single infusion of IVS‑3001, an autologous third‑generation CAR‑T targeting HLA‑G (an immune checkpoint ligand for ILT2/ILT4). Phase 2a includes cohorts for clear cell RCC post‑CPI/TKI, epithelial ovarian cancer post‑platinum (± prior PARP if BRCA1/2‑mutant), and other HLA‑G+ tumors without standard options.
ClinicalTrials.gov ID: NCT05672459
HealthScout AI summary: Adults with CLDN6-positive advanced solid tumors—emphasizing platinum-resistant/refractory ovarian cancer (also endometrial or testicular)—with measurable disease and ECOG 0–2 receive weekly IV CTIM-76, a CLDN6×CD3 T cell–engaging bispecific antibody, in dose escalation and expansion cohorts. Excludes active/untreated CNS disease, prior CLDN6 therapy, uncontrolled infection; treatment continues until progression or toxicity.
ClinicalTrials.gov ID: NCT06515613
HealthScout AI summary: Adults (≥18; ≥15 for germ cell tumors) with CLDN6-positive advanced ovarian/fallopian tube/primary peritoneal cancer, endometrial adenocarcinoma, or germ cell tumors after standard therapy receive XmAb541, an investigational CLDN6×CD3 bispecific T‑cell–engaging antibody given IV or SC with step-up dosing. Excludes prior CLDN6-directed therapy, platinum-refractory ovarian cancer or rapid progression on ≥2nd-line, uncontrolled CNS metastases, active autoimmune disease, and significant comorbidities.
ClinicalTrials.gov ID: NCT06276491
HealthScout AI summary: Adults with locally recurrent ovarian, fallopian tube, primary peritoneal, endometrial, cervical, or vaginal cancers confined to the abdomen/pelvis receive daily oral talazoparib, a PARP1/2 inhibitor and potent PARP trapper/radiosensitizer, starting before and during fractionated external-beam radiation. Eligible patients must have ECOG 0–1 (or adequate life expectancy), adequate organ function, and at least one non-previously-irradiated measurable lesion; prior RT to the planned field, carcinomatosis/ascites/hepatic metastases, or need for extended-field RT are excluded.
ClinicalTrials.gov ID: NCT03968406
HealthScout AI summary: Metastatic, platinum-resistant high-grade serous ovarian, fallopian tube, or primary peritoneal cancer (initially platinum-sensitive; ≤1 prior line for platinum-resistant disease; prior PARP allowed) treated with PLX038, a long-acting pegylated prodrug of SN-38 (topoisomerase I inhibitor) given IV every 21 days until progression/toxicity. Excludes non–HGS histology and patients with UGT1A1 deficiency (e.g., Gilbert’s or homozygous UGT1A1*28).
ClinicalTrials.gov ID: NCT05465941